Biotech firms' takeover premium is on the rise

04/24/2012 | Bloomberg Businessweek

Drugmakers relying on acquisitions to replenish their pipeline are increasing bids for biotech firms, driving the average premium higher, according to Bloomberg data. For biotech takeover targets valued at greater than $500 million, the premium over 20-day average share price is 71% this year, the most in at least 12 years.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX